In recent years, many clinical trials were conducted to evaluate therapy effects of CD19 Chimeric antigen receptor (CAR) T cells on r/r B-cell lymphoma, mainly r/r DLBCL. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.